

1. [Health experts welcome ease of clinical trials for academic research](#) – Mint

A recent notification by Union health Ministry amended Drugs & Cosmetics Act 1940, separating procedures of approval for trials for academic and marketing purposes. Suneela Thatte, President, ISCR said “Academic research is carried out on already approved drugs, which is different from conducting clinical trials for marketing purposes by pharmaceutical companies.”

The Indian Society for Clinical Research (ISCR) today said the March 16

gazette notification by the Health Ministry exempting clinical trials undertaken in medical institutions or hospitals for academic research from seeking permission would give a much needed boost to institutional research being conducted in India.

While India is the largest producer and exporter of generic medicines in the world, domestic research in new medicines is low. According to estimates, less than 1.5 per cent of the global clinical research is being conducted in India and red tapes are noted as a prominent cause for the slack.

Similar story in [ICSR welcomes Health Ministry's notification on clinical](#) – Business Standard
[Govt says no need for clinical trial approval for academics](#) – Hindu Business Line
[DCGI notification on academic research will boost local research...: ISCR](#) – Biospectrum

2. [HIV, diabetes, cancer drug prices may dip by up to 50%](#) - Hindustan Times

NPPA is studying drugs across therapeutic areas, including HIV, diabetes, cancer and tuberculosis to find drugs which are not under the NLEM list. The regulator will send requests within a month to state drug controllers across India to understand the availability of certain drugs in regular markets.

“We have just begun the process and it may not be right to fix a deadline as it is a responsible and time-consuming process,” says Bhupendra Singh, chairman, NPPA

3. [‘Indian drug control weakest in the world, needs strengthening’](#) – DNA

In an event on Tuesday, DoP, Secretary V K Subburaj said that the health ministry is working on improving specific parameters to bolster the drug control. He highlighted the issue of delay in problem solving and the need to have a proactive approach towards it, referred to the bulk drug pricing policy that may take long for implementation due to necessary approvals.

1. [Health experts welcome ease of clinical trials for academic research](#) – Mint
2. [HIV, diabetes, cancer drug prices may dip by up to 50%](#) - Hindustan Times
3. [‘Indian drug control weakest in the world, needs strengthening’](#) – DNA
4. [‘India makes all Mylan HIV drugs for developing world’](#) – Times of India
5. [US think tank launches India-US trade initiative](#) - PTI
6. [U.S. FDA warns Sri Krishna Pharma, citing drug-data manipulation](#) – Reuters
7. [Study reveals poor state of medical research](#) – Times of India
8. [CII organises 13th National Pharma Conclave](#) – Express Pharma
9. [‘Increase healthcare spending’](#) – Hindu Business Line
10. [Nilesh Gupta of Lupin new president of IPA; Glenn Saldanha of Glenmark vice-president](#) – Pharmabiz

4. [‘India makes all Mylan HIV drugs for developing world’](#) – Times of India
An interview with Rajiv Malik, President of Mylan spoke to TOI during his visit to Bengaluru. Responding to the R&D team and innovations in India, nearly 50% of those receiving treatment for HIV/AIDS in the developing world rely on Mylan products, all of which are made in India. On patent environment in India, he says, “I think India has done a good job in balancing the idea of affordability and protection of science. India respects the basic molecule and it's a fair play as you need generics to reach millions of people.”
5. [US think tank launches India-US trade initiative](#) - PTI
The Atlantic Council US-India Trade launched an initiative to strengthen support for continued economic engagement in India to collaborate on issues of trade and commerce. The Initiative will develop policy briefs and strategy papers, convene US-India trade workshops and host a flagship US-India Trade Conference with policymakers, practitioners and private-sector leaders. The initiative will address seven of the most crucial areas of the US-India trade relationship, including smart cities, infrastructure, defense, financial institutions, insurance, trade agreements and intellectual property rights.
6. [U.S. FDA warns Sri Krishna Pharma, citing drug-data manipulation](#) – Reuters
Sri Krishna Pharmaceuticals, Hyderabad based Drug Company is warned by US FDA on manipulation of its test results at a plant. The company supplies drug to more than 60 countries. The staff of the company’s plant deleted unfavourable test results and manipulated records to show products it made adhered to the quality standards. The company supplies several drugs such as anti-diabetic glipizide, the stomach disorder drug domperidone, and the diuretic furosemide, to the United States and Europe, among other countries. The warning was received after Canada’s health regulator stopped importing raw materials around a year back.
7. [Study reveals poor state of medical research](#) – Times of India
A study on the research output of all institutions in India during 2005-14 using Scopus, the largest database of peer-re-viewed literature revealed that a handful of institutes, a majority of them publicly-funded, account for the bulk of research output from medical institutions in India. Nearly 60% of institutes did not have a single publication over a decade. Moreover, states that have the largest number of private medical colleges produce very little of research publication
8. [CII organises 13th National Pharma Conclave](#) – Express Pharma
During the Tamil Nadu Health Summit 2016 organized by CII, Partner, McKinsey & Co, Prashanth Vasu said that the Government must increase healthcare spending and make it accessible to rural population. He spoke of focusing on creating physical access, increasing public health coverage and establishing publicly funded social insurance schemes.
9. [‘Increase healthcare spending’](#) – Hindu Business Line
Hansraj Ahir, Minister of State for Chemicals and Fertilisers, while addressing the conference urged the industry to come forward to address prospects and challenges in segments like manufacturing of bulk drug , medical equipment and on R&D. The minister observed that the pharma industry should make quality drugs at affordable prices to the common man.
10. [Nilesh Gupta of Lupin new president of IPA; Glenn Saldanha of Glenmark vice-president](#) – Pharmabiz
Lupin’s Managing Director Nilesh Gupta will assume charge as the president of Indian Pharmaceutical Alliance for 2015-17 and Glenn Saldanha, chairperson of Glenmark Pharmaceuticals, will be the vice-president, the association announced on Wednesday. The association represents domestic pharmaceutical companies and comprises of twenty members across India.